Bioenvision, Inc. (Nasdaq:BIVN) today announced Christopher B. Wood, M.D., chairman and chief executive officer of the Company...
Bioenvision, Inc. (Nasdaq: BIVN) today announced that it had priced its registered direct offering of 8 million shares of common...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced it has entered into a licensing arrangement with Foster Corporation to license...
Bioenvision Inc. (NasdaqGM:BIVN) will hold a live webcast of its quarterly conference call at 10:00a.m. EST on Thursday, February...
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Christopher B. Wood, M.D., Chairman and Chief Executive Officer of the...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced new efficacy, survival and safety data on Evoltra? from its pivotal Phase II...
Bioenvision, Inc. (NasdaqGM:BIVN) announced the latest results from clinical studies of clofarabine (Evoltra?) were presented...
Bioenvision, Inc. (NasdaqGM: BIVN) announced today the advertisement for its pediatric leukemia drug Evoltra? has been given...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced that data from its pivotal Phase II clinical trial of Evoltra? (clofarabine...
Bioenvision, Inc. (NasdaqGM:BIVN) today announced the appointment James S. Scibetta to the post of Chief Financial Officer. Mr...
Bioenvision, Inc. (NasdaqGM:BIVN) announced today it has filed a clinical trial authorization (CTA) to begin two Phase I studies...
Bioenvision (NasdaqGM:BIVN) today announced financial results for the first quarter ended September 30, 2006. Highlights of the...
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Dr. Christopher B. Wood, Chairman and Chief Executive Officer of the...
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2007 first quarter financial results at 7:00 a.m. Eastern Standard Time on...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.